ISHRS 2023 CME Webinar March 1 – All You Want to Know About Male Hair Loss Restoration

ISHRS 2023 CME Webinar

All You Want to Know About Male Hair Loss Restoration

Presented on
Wednesday, March 1, 2023
9AM to 11AM Central Time/Chicago
(Time Zone Conversion)
Duration: 2 hours

Available On Demand – Register below to view the recording

Registration Fees Per Webinar

Physician Attendee of ISHRS 2022 Panama World Congress$0.00 USD
ISHRS Physician Member
Non-Attendee of ISHRS 2022 Panama World Congress
$75.00 USD
ISHRS Physician Pending-Member
Non-Attendee of ISHRS 2022 Panama World Congress
$100.00 USD
Physician Non-Member
Non-Attendee of ISHRS 2022 Panama World Congress
$125.00 USD


Ratchathorn Panchaprateep, MD, PhD, FISHRS | Thailand
Rana M. Irfan, MBBS, FISHRS | Pakistan

Program Description

The live online webinar will occur on the date and time as noted. The live program will be recorded and available for viewing on demand until January 10, 2024. This 2-hour CME activity is a live webinar which will be recorded with the intention to be re-watched or viewed as on-demand education. This program is specifically for physicians doing hair transplant surgery, either FUE or LSE (FUT). This webinar is being conducted to furnish physicians’ knowledge on male hair loss from diagnosis and differential diagnosis to the medical and surgical treatments of hair loss in males, and consequently they will be able to provide better results to patients coming to their clinics for hair loss treatments.

The online live component will include presentations, panel discussion, and audience participation via verbal questions and discussion, and typed chat Q&A.

Professional Practice Gap

In our daily clinical practice, many patients present with mixed patterns of hair loss. For example, a patient presenting to the physician with Androgenetic Alopecia (AGA) may have alopecia areata at the same time. Accordingly, proper diagnosis and evaluation is very important in male hair loss. Many patients end up with surgical treatments for hair loss, but knowing where and when to avoid surgery is paramount.

Educational Need

Many male patients become bald before the age of 50. This is ideally addressed in earlier years with medical treatments of hair loss to avoid progression to higher grades of balding patterns. Importance of systemic medical treatments should be understood to optimally treat patients in the clinical practice of hair restoration surgery, while with surgical treatments the best and safe use of permanent donor area at different ages with different patterns of baldness must be understood. This is why early and proper diagnosis of the problem is important, involving clinical examination, medical history, trichoscopy and confirmation by trichogram, and/or biopsy if needed.

Hair transplant surgeons must understand the problems and medical and surgical treatment correlations, including ancillary treatments such as PRP or SMP.

Learning Objectives

As a result of participating in this webinar, the attendees should be able to:

  • Give proper diagnosis and recognize pathologies which are not very common in male hair loss.
  • Describe the management of androgenetic alopecia and other types of alopecia in men.
  • Discuss different surgical techniques and approaches in male hair loss.
  • Specify the specific moments to advise ancillary treatments in men, such as SMP, PRP and/or mesotherapy.

Target Audience and Prerequisites

This webinar is taught at the physician level. It is open to all levels and geared toward advanced hair restoration surgeons.


  1. Hair Transplantation, Unger, W (ed), 5th edition. Informa Healthcare, 2011.
  2. Hair Fact (Everything you ever wanted to know about hair loss and hair care), Tosti, A (ed), 1st edition. Elsevier, Aug 23, 2019.
  3. Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Nov;33(7):2946-2962.
  4. Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Mesotherapy with Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. J Drugs Dermatol. 2022 Jul 1;21(7):742-747.
  5. Melo DF, Saceda-Corralo D, Tosti A, Weffort F, Carla Jorge M, de Barros CC, de Melo Carvalho R, Starace M. Frontal edema due to mesotherapy for androgenetic alopecia: A case series. Dermatol Ther. 2022 Feb;35(2):e15247.

CME Information

Continuing Medical Education (CME) Credit Statement

The International Society of Hair Restoration Surgery is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Society of Hair Restoration Surgery designates this Other Activity (blended synchronous and enduring) for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive CME credit and a CME certificate, participants must participate in the activity, complete the evaluation survey and the CME Claim Form by January 10, 2024.


Internet/online, via computer or mobile device. 

Official Language

The official language of the webinar is English. Simultaneous interpretation is not provided for this webinar.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the ISHRS must ensure that anyone in a position to control the content of the educational activity (planners/ speakers/authors/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

  • Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
  • Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.  ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
  • Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ISHRS manage any reported conflict and eliminate the potential for bias during the educational activity.  Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Disclosures of Relevant Financial Relationships of Planners, Faculty, and Others

The following individuals have no relevant financial relationships with ineligible companies to disclose:


Conradin von Albertini, MD, FISHRS – Planner
Waris Anwar, MBBS, FISHRS – Planner
Marco N. Barusco, MD, FISHRS – Planner & COI Review Team
Victoria Ceh, MPA – Planner & Manager & COI Review Team
Bruno F. Ferreira, MD – Planner
Steven Gabel, MD, FISHRS – Planner
Robert S. Haber, MD, FISHRS – Planner & COI Review Team
James A. Harris, MD, FISHRS – Planner
Rana Irfan, MBBS, FISHRS – Planner
Emily Middag – Planner and Manager
Ratchathorn Panchaprateep, MD, PhD, FISHRS – Planner & COI Review Team
Mauro Speranzini, MD, FISHRS – Faculty
Melanie Stancampiano – Planner & Manager
Mark A. Waldman, MD – Planner


Jerry E. Cooley, MD, FISHRS – Faculty
Márcio Crisóstomo, MD, FISHRS – Faculty
Shady El-Maghraby, MD, MSc, FISHRS – Faculty
Rana Irfan, MBBS, FISHRS – Faculty
Samuel M. Lam, MD, FISHRS – Faculty
M. Humayun Mohmand, MD, FISHRS – Faculty
David S. Josephitis, DO, FISHRS – Faculty
Paulo Müller Ramos, MD, PhD – Faculty
Ratchathorn Panchaprateep, MD, PhD, FISHRS –Faculty
Mauro Speranzini, MD, FISHRS – Faculty

The following individuals have relevant financial relationships:




Sergio Vañó Galván, MD, PhD – Faculty:  Skymedic: Speaker  [Mesotherapy with dutasteride]; Cantabria labs: Speaker & Advisor [topical finasteride]

All of the relevant financial relationships listed for these individuals have been mitigated.

Commercial Support


Off-Label Or Other Non-FDA Approved, Investigational Use

Paulo Müller Ramos, MD, PhD – Finasteride and Dutasteride

Other CME Information

Click for Continuing Medical Education Mission Statement
Learner Bill of Rights
ISHRS Privacy and Confidentiality Policy for Internet CME


The webinar content has been made available by the ISHRS for educational purposes only. The content is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather is intended to present views, statements, and opinions that may be of interest to others. The views expressed herein are those of the individual authors and not necessarily those of the ISHRS. The ISHRS assumes no responsibility or liability in connection with your use or misuse of the webinar content or any materials or techniques described in the content, and it makes no warranty or representation as to the validity or sufficiency of any information provided.

Questions: Learners may contact the ISHRS Headquarters with questions about this CME activity at phone +1-800-444-2737 or +1-630-262-5399, or fax +1-630-262-1520, or email: [email protected]